Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:ANIPNYSE:ANVSNASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.88-2.2%$20.11$10.21▼$25.67$4.36B0.433.70 million shs1.83 million shsANIPANI Pharmaceuticals$64.91-0.6%$63.79$52.50▼$77.00$1.41B0.57313,301 shs219,339 shsANVSAnnovis Bio$2.39+1.3%$2.26$1.11▼$17.88$45.99M1.57508,468 shs333,083 shsLNTHLantheus$79.19-1.5%$82.10$73.11▼$126.89$5.56B0.121.02 million shs707,327 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.27%-1.81%-13.25%+0.11%+56.02%ANIPANI Pharmaceuticals-0.58%-0.52%+4.76%+2.95%+5.65%ANVSAnnovis Bio+0.21%+9.63%-25.27%+98.34%-78.47%LNTHLantheus-0.03%-3.26%-2.89%-15.22%+0.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.1231 of 5 stars3.72.00.00.03.02.53.1ANIPANI Pharmaceuticals3.6248 of 5 stars2.51.00.03.31.83.31.3ANVSAnnovis Bio1.4647 of 5 stars3.51.00.00.00.01.70.6LNTHLantheus4.4117 of 5 stars3.51.00.04.22.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6754.74% UpsideANIPANI Pharmaceuticals 3.00Buy$80.1323.44% UpsideANVSAnnovis Bio 3.00Buy$18.00653.14% UpsideLNTHLantheus 3.00Buy$130.5064.79% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.01$0.53 per share33.77$1.48 per share12.08ANIPANI Pharmaceuticals$614.38M2.29$7.56 per share8.59$19.11 per share3.40ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ALNTHLantheus$1.53B3.57$6.98 per share11.34$15.65 per share5.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8521.0425.91N/A45.01%47.16%30.51%8/6/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.42N/A-3.12%21.35%7.52%8/5/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)LNTHLantheus$312.44M$3.5222.5012.55N/A16.55%36.99%20.55%7/30/2025 (Estimated)Latest ANIP, ADMA, ANVS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36ANIPANI Pharmaceuticals1.462.661.98ANVSAnnovis BioN/A10.6810.68LNTHLantheus0.495.745.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%LNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%ANIPANI Pharmaceuticals12.70%ANVSAnnovis Bio20.80%LNTHLantheus2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableLNTHLantheus70069.19 million67.80 millionOptionableANIP, ADMA, ANVS, and LNTH HeadlinesRecent News About These Companies1 Safe-and-Steady Stock on Our Watchlist and 2 to Keep Off Your RadarJuly 7 at 6:17 AM | finance.yahoo.comNew York State Teachers Retirement System Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 5 at 4:26 AM | marketbeat.comAllspring Global Investments Holdings LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 3, 2025 | marketbeat.comLantheus’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJuly 2, 2025 | msn.comKeybank National Association OH Has $56.30 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)July 2, 2025 | marketbeat.comLantheus Seems Worth The (Very Real) RisksJuly 1, 2025 | seekingalpha.comContrasting RBC Life Sciences (OTCMKTS:RBCL) and Lantheus (NASDAQ:LNTH)July 1, 2025 | americanbankingnews.comPeregrine Capital Management LLC Sells 5,148 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)June 30, 2025 | marketbeat.comRiley Maintains ‘Buy’ Rating on Lantheus Holdings, Inc. (LNTH); Lowers PTJune 29, 2025 | insidermonkey.comLisanti Capital Growth LLC Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 29, 2025 | marketbeat.comLantheus Holdings Inc Analysis & Opinion (LNTH) - Investing.comJune 28, 2025 | investing.comLNTH - Lantheus Holdings Inc Trailing Returns | MorningstarJune 26, 2025 | morningstar.comMJanney Montgomery Scott LLC Increases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 26, 2025 | marketbeat.comSpotting Winners: Lantheus (NASDAQ:LNTH) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q1June 25, 2025 | msn.comLantheus Holdings, Inc. (LNTH) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comLantheus to Present New Oncology Radiodiagnostic Data at SNMMI MeetingJune 24, 2025 | msn.comB. Riley Issues Pessimistic Forecast for Lantheus (NASDAQ:LNTH) Stock PriceJune 23, 2025 | marketbeat.comExchange Traded Concepts LLC Raises Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 21, 2025 | marketbeat.comLantheus Holdings (NasdaqGM:LNTH) Joins FIBRE Consortium To Transform Fibrotic Disease TreatmentJune 21, 2025 | uk.finance.yahoo.comRiverwater Partners LLC Has $1.40 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)June 20, 2025 | marketbeat.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Buy" from AnalystsJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANIP, ADMA, ANVS, and LNTH Company DescriptionsADMA Biologics NASDAQ:ADMA$17.88 -0.40 (-2.19%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$18.31 +0.43 (+2.40%) As of 07/7/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$64.91 -0.37 (-0.57%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$64.84 -0.07 (-0.11%) As of 07/7/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$2.39 +0.03 (+1.27%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$2.36 -0.03 (-1.26%) As of 07/7/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Lantheus NASDAQ:LNTH$79.19 -1.23 (-1.53%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$79.49 +0.30 (+0.38%) As of 07/7/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
